Fig. 2From: Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)Cumulative pain and pain-free hours calculated over 52-weeks, for two scenarios. Figure 2illustrates the following two scenarios: 1) patients switch to rimegepant, and 2) patients continue with baseline standard of care treatmentBack to article page